Medizinische Universität Graz - Research portal
Sill Heinz |
Presentations at scientific and public conferences
Alihodžić, D; Özkaya, E; Foßelteder, J; Sconocchia, T; Auinger, L; Schlenke, P; Sill, H; Zebisch, A; Wölfler, A; Vujić, N; Kratky, D; Reinisch, A
Investigating the contribution of TET2 mutant human clonal hematopoiesis to human atherosclerotic plaque formation in a novel LDLR/ApoE double knock-out mouse model.
Doctoral Day 2024; 08.02.2024; Graz, AUSTRIA. 2024.
[Poster]
Alihodžić, D; Özkaya, E; Foßelteder J; Sconocchia, T; Auinger, L; Schlenke, P; Sill, H; Zebisch, A; Wölfler A; Vujić, N; Kratky, D; Reinisch A
CRISPR/Cas9 genome engineering to model TET2 mutant human clonal hematopoiesis and its pro-atherogenic potential.
Austrian Atherosclerosis Society (AAS) Annual Meeting; MAI 2-4, 2024; St. Gilgen, AUSTRIA. 2024.
[Poster]
ALIHODŽIĆ, D; ÖZKAYA1, E; PABST, G; FOßELTEDER, J; SCONOCCHIA, T; AUINGER, L; SCHLENKE, P; SILL1, H; ZEBISCH, A; WÖLFLER, A; REINISCH, A
Modeling SRSF2/TET2 mutational cooperativity in CMML development
European Hematology Association (EHA) 2024 Hybrid Congress; JUNE 13-16, 2024; Madrid, SPAIN. 2024.
[Poster]
Cutillas, PR; Borek, WE; Christopher, JA; Nobre, LV; Campbell, A; Kelsall, J; Pedicona, F; Nawaz, N; Perkins, DN; Cardoso, PM; Arruda, A; Ambinder, AJ; Dutta, S; Gallipoli, P; Sill, H; Ghiaur, G; Minden, MD; Williamson, A; Gribben, JG; Dokal, AD
Multi-drug algorithm to accurately predict best first-line treatments in newly-diagnosed acute myeloid leukemia (AML)
J CLIN ONCOL. 2024; 42(16):
[Poster]
Web of Science
Dutta, S; Rezania, S; Lyssy, F; Lind, K; Vosberg, S; Thallinger, G; Zebisch, A; Wölfler, A; Pabst, G; Foßelteder, J; Reinisch, A; Sill, H;
Deciphering the molecular mechanism of mesenchymal stromal cell mediated drug resistance in acute myeloid leukemia.
29th European Hematology Association Congress; JUN 13-16, 2024; Madrid, SPAIN. 2024.
[Poster]
Edtmayer, S; Witalisz-Siepracka, A; Zdársky, B; Weiss, S; Eder, T; Dutta, S; Wieser, R; Sill, H; Grebien, F; Stoiber, D
STAT3β represses interferon signaling in acute myeloid leukemia contributing to favorable disease outcomes
KLIN PADIATR. Abstracts. 2024; 236(3):204-204.-35. Jahrestagung der Kind-Philipp-Stiftung für pädiatrisch onkologische Forschung; JUN 5-8, 2024; Wilsede, GERMANY.
Doi: 10.1055/s-0044-1786570
[Poster]
Web of Science
FullText
FullText_MUG
Foßelteder, J; Brauchart, T; Schlacher, A; Sconocchia, T; Özkaya, E; Auinger, L; Schlenke, P; Sill, H; Zebisch, A; Reinisch, A;
Engineered cytokine-expressing mesenchymal stromal cells support ex vivo culture of human HSPCs and AML cells.
BMS Future Talks; SEP 27-28, 2024; Vienna, AUSTRIA. 2024.
[Poster]
Lind, K; Dutta, S; Foßelteder, J; Pabst, G; Reinisch, A; Wölfler, A; Zebisch, A; Sill, H;
Deciphering early steps of TP53 aberrant human leukemogenesis.
29th European Hematology Association Congress; JUN 13-16, 2024; Madrid, SPAIN. 2024.
[Poster]
Özkaya, E; Sconocchia, T; Foßelteder, J; Alihodzic, D;
Schlacher, A; Auinger, L; Schlenke, P; Sill, H; Zebisch, A; Reinisch, A
Genome engineered TET2 loss-of-function mutations increase stem cell self-renewal in human hematopoietic stem and progenitor cells.
Doctoral Day (DocDay); FEB 08 2024; Graz, Austria. 2024.
[Poster]
Kuendgen, A; Nomdedeu, M; Tuechler, H; Garcia-Manero, G; Komrokji, R; Sekeres, M; Della Porta, M; Cazzola, M; Dezern, A; Roboz, G; Steensma, D; Van De Loosdrecht, A; Malcovati, L; Schlenk, R; Grau, J; Calvo, X; Blum, S; Pereira, A; Valent, P; Costa, D; Giagounidis, A; Xicoy, B; Dohner, H; Platzbecker, U; Pedro, C; Lubbert, M; Oiartzabal, I; Diez-Campelo, M; Cedena, MT; Machherndl-Spandl, S; Lopez-Pavia, M; Martinez-De-Sola, M; Stauder, R; Merchan, B; Ganster, C; Schroeder, T; Voso, MT; Pfeilstocker, M; Sill, H; Hildebrandt, B; Esteve, J; Cobo, F; Sole, F; Germing, U; Greenberg, P; Haase, D; Sanz, G
A STEP TOWARDS IDENTIFICATION AND CAUSAL INTERPRETATION OF THERAPY-RELATED MDS (T-MDS)
LEUKEMIA RES. 2023; 128: 107226-
Doi: 10.1016/j.leukres.2023.107226
[Oral Communication]
Web of Science
FullText
FullText_MUG
Lyssy, F; Lind, K; Zöscher, F; Zebisch, A; Wölfler, A; Pabst, G; Fosselteder, J; Reinisch, A; Sill, H; Dutta, S
Modelling drug resistance conferred by mono- and bi-allelic TP53 aberrations using isogenic AML cell lines
ONCOL RES TREAT. 2023; 46: 188-189.
[Poster]
Web of Science
FullText
Dutta,S; Moritz,J; Pregartner,G; Thallinger,G; Brandstätter, I; Lind,K; Rezania,S; Lyssy,F; Reinisch,A; Zebisch,A; Berghold,A;Wölfler, A and Sill, H
AML and MDS patients with TP53 aberrations – a single cancer center experience.
Magazine of European Medical Oncology“. 2022; -Frühjahrestagung ÖGHO 2022; APR 8-10 2022; Graz, Austria.
[Oral Communication]
Gaksch, L; Huber-Krassnitzer, B; Uhl, B; Bainschab, A; Sifferlinger, I; Sill, H; Schlenke, P; Rosskopf, K; Beham-Schmid, C; Neumeister, B; Greinix, HT
Autologous stem cell transplantation as rescue
therapy for prolonged cytopenia after treatment
with CD19-targeted chimeric antigen receptor
modifed T-cells: two case reports
Frühjahrstagung 2022 der OeGHO; APR 8-10,2022; Graz. 2022.
[Poster]
FullText
Gaksch, L; Huber-Krassnitzer, B; Uhl, B; Bainschab, A; Sifferlinger, IA; Sill, H; Schlenke, P; Rosskopf, K; Beham-Schmid, C; Neumeister, P; Greinix, HT
Autologous stem cell boost for prolonged severe cytopenia after treatment with cd19-car-t-cells for refractory diffuse large b-cell lymphoma -two case reports
BONE MARROW TRANSPL. 2022; 57(SUPPL 1): 141-142.
[Poster]
Web of Science
FullText
Pabst, G; Foßelteder, F; Schlacher, A; Auinger, L; Martinez-Krams, D; Ediriwickrema, A; Kashofer, K; Beham-Schmid, Ch; Greinix, HT; Woelfler, A; Schlenke, P; Sill, H; Zebisch, A; Majeti, R; Reinisch, A;
Modeling the Development of SRSF2 Mutated Myeloid Malignancies By CRISPR/Cas9 Mediated Genome Engineering of Primary Human Hematopoietic Stem and Progenitor Cells.
Blood (2021) 138 (Supplement 1): 2160.. 2022; 138: 2160-2160.-ASH Annual Meeting 2021; DEZ 11-14, 2021; Atlanta, USA.
[Poster]
FullText
Pleyer, L; Vaisband, M; Pfeilstocker, M; Stauder, R; Heibl, S; Sill, H; Girschikofsky, M; Stampfl-Mattersberger, M; Tinchon, C; Hartmann, BL; Petzer, A; Schreder, M; Schmitt, CA; Vallet, S; Melchardt, T; Scagnetti, L; Zebisch, A; Machherndl-Spandl, S; Wolf, D; Keil, F; Hasenauer, J; Greil, R
Cox Proportional Hazards Deep Neural Network Identifies Peripheral Blood Complete Remission (PB-CR) to be at Least Equivalent to Morphologic CR in Predicting Outcomes of Patients Treated with Azacitidine - a Prospective Cohort Study By the AGMT
BLOOD. 2022; 140: 1346-1349.
Doi: 10.1182/blood-2022-168521
[Oral Communication]
Web of Science
FullText
FullText_MUG
Telebar, F; Berg, JL; Perfler, B; Bramreiter, B; Caraffini, V; Prokesch, A; Geissler, K; Penz, T; Schuster, M; Reinisch, A; Wölfler, A; Sill, H; Zebisch, A;
Co-occurrence of mutations modifying RAS and EZH2 inactivation in chronic myelomonocytic leukemia causes amplification of RAS-AKT signaling and increases the sensitivity to AKT inhibitors
Proceedings of the Annual Meeting of the Austrian Society of Haematology and Medical Oncology. memo 15 (Suppl 3), 37–67 (2022). . 2022; 15( ):S65--OeGHO- & AHOP-Frühjahrstagung 2022; April 8-10, 2022; Graz, Austria.
[Oral Communication]
FullText
Berg, JL; Perfer, B; Hatzl, S; Reinisch, A; Pregartner, G; Klymiuk, I; Tierling, S; Geissler, G; Strobl, H; Berghold, A; Wölfer, A; Sill, H; Zebisch, A
Aberrant expression of micro-RNA-125a plays a role in the pathogenesis and treatment of chronic myelomonocytic leukemia – Update
memo - Proceedings of the Annual Meeting of the Austrian Society
of Haematology and Medical Oncology. 2021; 14: -Annual Meeting of the Austrian Society
of Haematology and Medical Oncology; APR 8-10, 2021; Wien.
[Poster]
Foßelteder, J; Rosenberger, A; Pabst, G; Sill, H; Wölfler, A; Reinisch, A
Calreticulin mutations transform healthy hematopoietic stem cells into myeloproliferative neoplasms.
Doctoral Day 2021 at Medical University of Graz; FEB 12, 2021; Graz, AUSTRIA. 2021.
[Onlinepräsentation]
Foßelteder, J; Schlacher, A; Pabst, G; Amtmann, B; Schöll, W; Kashofer, K; Beham-Schmid, C; Schlenke, P; Greinix, HT; Sill, H; Woelfler, A; Zebisch, A; Reinisch, A
Introduction and Genetic Correction of Calreticulin Mutations in Human Hematopoietic Stem and Progenitor Cells Sheds Light on MPN Pathogenesis
Blood. 2021; 138(S1):-Annual Meeting of the American Society of Hematology (ASH); DEC 11-14, 2021; Atlanta, USA.
Doi: 10.1182/blood-2021-147919
[Poster]
Web of Science
FullText
FullText_MUG
Kuendgen, A; Nomdedeu, M; Tuechler, H; Garcia-Manero, G; Komrokji, R; Sekeres, M; Della Porta, M; Cazzola, M; Malcovati, L; Dezern, A; Roboz, G; Steensma, D; Haase, D; Stauder, R; Cedena, MT; De Loosdrecht, AV; Schlenk, R; Blum, S; Grau, J; Calvo, X; Valent, P; Costa, D; Pereira, A; Xicoy, B; Dohner, H; Platzbecker, U; Giagounidis, A; Pedro, C; Lubbert, M; Oiartzabal, I; Diez-Campelo, M; Machherndl-Spandl, S; Lopez-Pavia, M; Martinez-De-Sola, M; Merchan, B; Ganster, C; Schroeder, T; Voso, MT; Hildebrandt, B; Esteve, J; Nomdedeu, B; Cobo, F; Haas, R; Sole, F; Germing, U; Greenberg, P; Sill, H; Pfeilstocker, M; Sanz, G
COMPARISON OF CYTOGENETIC ABERRATIONS IN 1590 PATIENTS WITH THERAPY-RELATED MDS (T-MDS) AND 4738 PATIENTS FROM THE REVISED INTERNATIONAL PROGNOSTIC SCORING SYSTEM DATABASE WITH PRIMARY-MDS (P-MDS)
LEUKEMIA RES. Abstracts Supplement. 2021; 108: S20-S21.-16th International Congress on Myelodysplastic Syndromes; SEP 23-26, 2021; Virtuell.
[Poster]
Web of Science
Pabst, G; Foßelteder, J; Schlacher, A; Auinger, L; Martinez-Krams3, D; Ediriwickrema, A; Kashofer, K; Beham-Schmid, C; Greinix, HT; Woelfler, A; Schlenke, P; Sill, H; Zebisch, A; Majeti, R; Reinisch, A
Modeling the Development of SRSF2 Mutated Myeloid Malignancies By CRISPR/Cas9 Mediated Genome Engineering of Primary Human Hematopoietic Stem and Progenitor Cells
Blood. 2021; 138(S1):-Annual Meeting of the American Society of Hematology (ASH); DEC 11-14, 2021; Atlanta, USA.
Doi: 10.1182/blood-2021-149591
[Poster]
Web of Science
FullText
FullText_MUG
Pleyer, L; Pfeilstocker, M; Stauder, R; Heibl, S; Sill, H; Girschikofsky, M; Stampfl-Mattesberger, M; Tinchon, C; Hartmann, B; Petzer, A; Petricevic, B; Schmitt, CA; Vallet, S; Geissler, K; Sperr, WR; Leisch, M; Egle, A; Melchardt, T; Piringer, G; Zebisch, A; Machherndl-Spandl, S; Wolf, D; Keil, F; Angermann, H; Drost, M; Larcher-Senn, J; Greil, R
Peripheral Blood Complete Remission Provides Added Value to the Classical Definition of Morphologic Complete Remission – a Prospective Cohort Study of 1441 Patients with MDS, CMML and AML Treated within the Austrian Azacitidine Registry
Englisch. 2021; 138(S1):-Annual Meeting of the American Society of Hematology (ASH); DEC 11-14, 2021; Atlanta, USA.
Doi: 10.1182/blood-2021-145401
[Poster]
Web of Science
FullText
FullText_MUG
Moser, T; Waldispuehl-Geigl, J; Belic, J; Perakis, S; Weber, S; Zhou, Q; Sill, H; Lax, S; Kashofer, K; Hoefler, G; Schoellnast, H; Bauernhofer, T; Heitzer, E; Geigl, JB; Speicher, MR
Early circulating tumor DNA dynamics as a real-time predictor of FOLFOX efficacy in advanced colorectal cancer patients
CANCER RES. 2020; 80(16):
Doi: 10.1158/1538-7445.AM2020-4295
[Poster]
Web of Science
FullText
FullText_MUG
Berg, JL; Perfler, B; Hatzl, S; Reinisch, A; Geissler, K; Strobl, H; Wölfler, A; Sill, H; Zebisch, A
Expression of miR-125a is decreased in chronic myelomonocytic leukemia and of relevance for the treatment with 5-azacytidine
Proceedings of the Annual Meeting of the Austrian Society of Haematology and Medical Oncology, Magazine of European Medical Oncology. 2019; 12: 53--Annual Meeting of the Austrian Society of Haematology and Medical Oncology; APR 11-13, 2019; Linz, AUSTRIA.
[Poster]
Dutta S, Pregartner G, Rücker FR, Heitzer H, Zebisch A, Bullinger L, Berghold A, Döhner K, Sill H
Functional Classification of TP53 Mutations in Acute Myeloid Leukemia
Blood. 2019; 134, Suppl. 1: -American Society of Hematology, Annual Meeting; DEC 6-10, 2019; Orlando.
[Poster]
DuttaS, Pregartner G, Rücker F, Heitzer E,Zebisch A, Bullinger L,Berghold A, Döhner K Sill H
Functional Classification of TP53 Mutations in Acute Myeloid Leukemia
German-Austrian Acute Myeloid Leukemia study group (AML-SG) Study meeting ; May 23-24, 2019; Vienna, Austria. 2019.
[Oral Communication]
Eisenwort G, Keller A, Willmann M, Sadovnik I, Greiner G, Gleixner KV, Ivanov D, Daniela Berger D, Stefanzl G, Winding C, Hoermann G, Sperr WR, Sill H, Bettelheim P, Geissler K, Deininger MW, Rülicke T, Valent P
Phenotypic Characterization of Leukemia-Initiating Stem Cells in Chronic Myelomonocytic Leukemia (CMML)
Blood. 2019; 134, Suppl. 1: -American Society of Hematology, Annual Meeting; DEC 6-10, 2019; Orlando.
[Poster]
Foßelteder, J; Wölfler, A; Kargl, J; Schöll, W; Schlenke, P; Sill, H; Reinisch, A
In-vitro modeling of JAK2 V617F-driven myeloproliferative neoplasms
using CRISPR/Cas9 genome engineering.
DocDay 2019, Medical University of Graz; 21.11.2019; Graz, AUSTRIA. 2019.
[Poster]
Krall N, Meszaros N, Lind K, Vilagos B, Sill H, Vladimer GI.
Functional Precision Medicine in AML: Technical Performance Evaluation for in Vitro Diagnostics Using High-Throughput Image-Based Screening of Primary Patient Cells
Blood. 2019; 134, Suppl. 1: -American Society of Hematology, Annual Meeting; DEC 6-10, 2019; Orlando.
[Poster]
Pleyer L, Pfeilstocker M, Stauder R, Heibl S, Sill H, Girschikofsky M, Stampfl-Mattersberger M, Tinchon C, Petzer A, Schmitt CA, Vallet S, Mandac I, Geissler K, Sperr WR, Leisch M, Egle A, Melchardt T, Fusinato J, Piringer G, Zebisch A, Machherndl-Spandl S, Wolf D, Keil F, Greil R,
Expanding on Current Definitions of Hematologic Improvement in MDS, CMML and AML: Landmark Analyses of 1301 Patients Treated with Azacitidine in the Austrian Registry of Hypomethylating Agents By the AGMT-Study Group
Blood. 2019; 134, Suppl. 1: -American Society of Hematology, Annual Meeting; DEC 6-10, 2019; Orlando.
[Poster]
Ulz, P; Perakis, S; Zhou, Q; Moser, T; Belic, J; Lazzeri, I; Wölfler, A; Zebisch, A; Gerger, A; Pristauz, G; Petru, E; White, B; Roberts, C; St. John, J; Schimek, MG; Geigl, JB; Bauernhofer, T; Sill, H; Bock, C; Heitzer, E; Speicher,M
Inference of tumor cell-specific transcription factor binding from cell-free DNA enables tumor subtype prediction
Circulating Nucleic Acids in Plasma and Serum (CNAPS); SEP 23-25, 2019; Jerusalem, Israel. 2019.
[Poster]
FullText
Bärnthaler, Th; Jandl, K; Sill, H; Uhl, B; Schreiber, Y;
Thomas, D; Schicho, R; Marsche, G; Frank, S; Heinemann, A; Schuligoi, R
IMATINIB AND NILOTINIB ARE STRONG STIMULATORS OF PGE2 SYNTHESIS AND ATTENUATE INFLAMMATORY CYTOKINE RELEASE VIA EP4 RECEPTOR ACTIVATION.
7th European Workshop on Lipid Mediators; SEP 12-14, 2018; Brussels, BELGIUM. 2018.
[Poster]
Caraffini, V; Geiger, O; Rosenberger, A; Hatzl, S; Perfler, B; Berg, JL; Lim, C; Strobl, H; Kashofer, K; Hoefler, G; Geissler, K; Kolch, W; Blyth, K; Athineos, D; Wolfler, A; Sill, H; Zebisch, A
Loss of RKIP expression is a frequent event in chronic myelomonocytic leukemia and functionally involved in the pathogenesis of this malignancy
ONCOL RES TREAT. 2018; 41: 27-27.
[Oral Communication]
Web of Science
Daga, S; Rosenberger, A; Krisper, N; Prietl, B; Reinisch, A; Zebisch, A; Sill, H; Wolfler, A
GPR56 and CLL-1 (CLEC12A) as putative leukemic stem cell markers in CD34-positive acute myeloid leukemia
ONCOL RES TREAT. 2018; 41: 73-73.
[Poster]
Web of Science
Daga, S; Rosenberger, A; Krisper, N; Reinisch, A; Zebisch, A; Sill, H; Wölfler, A
GPR56 is a putative marker of leukemic stem cells in CD34-positive acute myeloid leukemia.
Proceedings of the Annual Meeting of the Austrian Society of Haematology and Medical Oncology. 2018; Supplement 1/18: -Annual Meeting of the Austrian Society for Hematology and Medical Oncology; APR, 19-21, 2018; Villach, AUSTRIA.
[Poster]
Geissler, K; Barna, A; Jager, E; Gurbisz, M; Alendar, T; Ljubuncic, E; Jilch, R; Nosslinger, T; Pfeilstocker, M; Tuchler, H; Reisner, R; Sliwa, T; Keil, F; Geissler, C; Burgstaller, S; Thaler, J; Machherndl-Spandl, S; Zach, O; Weltermann, A; Bettelheim, P; Stauder, R; Borjan, B; Zebisch, A; Sill, H; Schwarzinger, I; Hormann, G; Jager, U; Sperr, WR; Knobl, P; Schneeweiss, B; Berger, J; Ohler, L; Ulsperger, E; Kusec, R; Germing, U; Valent, P
The role of RAS pathway hyperactivation in the progression and transformation of chronic myelomonocytic leukemia
ONCOL RES TREAT. 2018; 41: 238-238.
[Oral Communication]
Web of Science
Hatzl, S; Ebner, S; Perfler, B; Quehenberger, F; Troppmair, J; Reinisch, A; Wolfler, A; Sill, H; Zebisch, A
Deregulation of the micro-RNA-23a/TOP2B axis causes resistance to cytarabine in acute myeloid leukemia
ONCOL RES TREAT. 2018; 41: 243-243.
[Oral Communication]
Web of Science
Hatzl, S; Ebner, S; Perfler, B; Quehenberger, F; Troppmair, J; Reinisch, A; Wölfler, A; Sill, H; Zebisch, A
Increased expression of micro-RNA-23a causes resistance to cytarabine in acute myeloid leukemia.
Proceedings of the Annual Meeting of the
Austrian Society of Haematology and Medical Oncology
. 2018; Supplement 1/18: 26-26.-Annual Meeting of the Austrian Society for Hematology and Medical Oncology; APR, 19-21, 2018; Villach, AUSTRIA.
[Oral Communication]
Muralikrishnan, AS; Rosenberger, A; Schwarzenberger, E; Strobl, H; Zebisch, A; Sill, H; Wolfler, A
A role of C/EBP alpha in early dendritic cell development
ONCOL RES TREAT. 2018; 41: 102-102.
[Poster]
Web of Science
Pabst, G; Prochazka, K; Pregartner, G; Rücker, FG; Heitzer, E; Woelfler ,A; Zebisch, A; Berghold, A; Döhner, K; Sill H.
Impact of TP53 mutated subclones in acute myeloid leukemia
Blood. 2018; 132(Suppl ):-Annual Meeting of the American Society of Hematology; December 1-4, 2018; San Diego.
Doi: 10.1182/blood-2018-99-110667
[Poster]
Web of Science
FullText
FullText_MUG
Sill, H
TP53 mutated acute myeloid leukemia
ONCOL RES TREAT. . 2018; 41: 257-257.-Jahrestagung der Deutschen, Österreichischen und Schweizerischen Gesellschaften für Hämatologie und Medizinische Onkologie; SEP 28-OCT 2, 2018; Vienna, AUSTRIA.
[Poster]
Web of Science
Unterluggauer, J; Prochazka, K; Tomazic, PV; Huber, HJ; Seeboeck, R; Fechter, K; Steinbauer, E; Gruber, V; Rinner, B; Pichler, M; Weniger, M; Kueppers, R; Sill, H; Schicho, R; Neumeister, P; Beham-Schmid, C; Deutsch, A; Haybaeck, J;
Molecular expression analysis reveals potential of translation initiation factors to serve as novel biomarkers for aggressive B-cell lymphomas.
Der Pathologe 39:67-68. 2018; -102. Jahrestagung der Deutschen Gesellschaft für Pathologie; MAY 24-26, 2018; Berlin, GERMANY.
[Oral Communication]
FullText
Unterluggauer, JJ; Prochazka, K; Tomazic, PV; Huber, HJ; Seeboeck, R; Fechter, K; Steinbauer, E; Gruber, V; Feichtinger, J; Pichler, M; Weniger, MA; Kuppers, R; Sill, H; Schicho, R; Neumeister, P; Beham-Schmid, C; Deutsch, A; Haybaeck, J
Translation initiation factors are over-expressed in aggressive lymphomas and influence their clinical course
ONCOL RES TREAT. 2018; 41: 164-164.
[Poster]
Web of Science
Unterluggauer, JJ; Prochazka, K; Tomazic, PV; Huber, HJ; Seeboeck, R; Fechter, K; Steinbauer, E; Gruber, V; Feichtinger, J; Rinner, B; Pichler, M; Weniger, M; Küppers, R; Sill, H; Schicho, R; Neumeister, P; Beham-Schmid, C; Deutsch, AJA; Haybaeck, J
Specific translation initiation factors influence clinical course of aggressive lymphomas
OeGHO- & AHOP-Frühjahrstagung 2018; APR 19-21, 2018; Villach, AUSTRIA. 2018.
[Oral Communication]
Aberer, F; Holzgruber, J; Tripolt, NJ; Zebisch, A; Greinix, H; Sill, H; Mader, JK; Pieber, TR; Wölfler, A; Sourij, H
Efficacy and safety of an insulin decision support system in the treatment of steroid hyperglycaemia in patients with graft-versus- host-disease: a randomised pilot trial.
Diabetologia. 2017; 60(S1):S323-S324.-53rd Annual Meeting of the European Association for the Study of Diabetes (EASD); SEP 11-15, 2017; Lisbon, PORTUGAL.
[Poster]
Web of Science
Aberer, F; Mader, JK; Stauber, M; Neumeister, P; Oulhaj, Abderrahim; Zebisch, A; Pieber, TR; Greinix, H; Sill, H; Woelfler, A; Sourij, H
Early Hyperglycemia after Initiation of Glucocorticoid Therapy Predicts Adverse Outcome in Patients with Acute Graft-vs.-Host Disease.
Diabetes.. 2017; 66(S1):A24-A25.-77th Scientific Sessions of the American Diabetes Association (ADA); JUN 9-13, 2017; San Diego, CA, USA.
[Oral Communication]
Aberer, F; Mader, JK; Stauber, M; Tripolt, N; Holzgruber, J; Zebisch, A; Pieber, TR; Neumeister, P; Greinix, H; Sill, H; Wölfler, A; Sourij, H
Early hyperglycaemia after initiation of glucocorticoid therapy predicts adverse outcome in patients with acute graft-versus-host disease.
4th International Hospital Diabetes Meeting. 2017; MAY 19-20, 2017; Atlanta, USA.
[Poster]
Caraffini, V; Geiger, O; Rosenberger, A; Hatzl, S; Perfler, B; Berg, JL; Lim, C; Strobl, H; Kashofer, K; Hoefler, G; Geissler, K; Kolch, W; Blyth, K; Athineos, D; Woelfler, A; Sill, H; Zebisch, A
LOSS OF RAF KINASE INHIBITOR PROTEIN IS INVOLVED IN MYELOMONOCYTIC LINEAGE COMMITMENT AND AGGRAVATES THE DEVELOPMENT OF CHRONIC MYELOMONOCYTIC LEUKEMIA IN A MURINE IN-VIVO MODEL
HAEMATOLOGICA. 2017; 102: 148-149.-22nd Congress of the European-Hematology-Association; JUN 22-25, 2017; Madrid, SPAIN.
[Oral Communication]
Web of Science
Caraffini, V; Geiger, O; Rosenberger, A; Hatzl, S; Perfler, P; Berg, JL; Lim, C; Strobl, H; Kashofer, K; Hoefler, G; Geissler, K; Kolch, W; Blyth, K; Athineos, D; Wölfler, A; Sill, H; Zebisch, A
RAF kinase inhibitor protein is involved in the development of chronic myelomonocytic leukemia
memo - Magazine of European Medical Oncology. 2017; 10(2):21-21.-Annual Meeting of the Austrian Society of Haematology and Medical Oncology; APR 6-8, 2017; Bregenz, AUSTRIA.
[Poster]
Caraffini, V; Schauer, S; Kashofer, K; Wolfler, A; Hoefler, G; Sill, H; Zebisch, A
RAF KINASE INHIBITOR PROTEIN IS INVOLVED IN THE DEVELOPMENT OF MYELOID SARCOMA
HAEMATOLOGICA. 2017; 102: 361-362.-22nd Congress of the European-Hematology-Association; JUN 22-25, 2017; Madrid, SPAIN.
[Poster]
Web of Science
Caraffini, V; Schauer, S; Kashofer, K; Wölfler, A; Hoefler, G; Sill, H; Zebisch A
Loss of RAF kinase inhibitor Protein in myeloid sarcoma
memo - Magazine of European Medical Oncology
. 2017; 10(2):31-31.-Annual Meeting of the Austrian Society of Haematology and Medical Oncology
; APR 6-8, 2017; Bregenz, AUSTRIA.
[Poster]
Daga, S; Krisper, N; Zebisch, A; Sill, H; Wölfler, A
GPR56 is a putative leukemic stem cell marker with prognostic significance in acute myeloid leukemia.
4th International Conference on Acute Myeloid Leukemia; OCT 5-7, 2017; Estoril, PORTUGAL. 2017.
[Poster]
Gaksch, L; Kashofer, K; Heitzer, E; Daga, S; Hofer, S; Krisper, N; Hofler, G; Zebisch, A; Sill, H; Wolfler, A
Persistence of non-DNMT3A mutations predicts relapse in cytogenetically normal AML
ONCOL RES TREAT. 2017; 40: 140-141.
[Oral Communication]
Web of Science
Geissler, K; Barna, A; Jäger, E; Alendar, T; Ljubuncic, E; Jilch, R; Nösslinger, T; Pfeilstöcker, M; Tüchler, H; Reisner, R; Sliwa, T; Keil, F; Burgstaller, S; Thaler, J; Machherndl-Spandl, S; Zach, O; Weltermann, A; Bettelheim, P; Stauder, R; Schwarzinger, I; Hörmann, G; Jäger, U; Sperr, RW; Knöbl, P; Schneeweiss, B; Berger, J; Kusec, R; Öhler, L; Zebisch, A; Sill, H; Germing, U; Valent, P
High spontaneous in-vitro myeloid colony growth is an adverse risk factor in chronic myelomonocytic leukemia
Oncol Res Treat. 2017; 40(S3):131-131.-Jahrestagung der Deutschen, Österreichischen und Schweizerischen Gesellschaften für Hämatologie und Medizinische Onkologie; SEP 29 - OCT 3, 2017; Stuttgart, GERMANY. (ISBN: 978-3-318-06110-9 )
[Oral Communication]
Web of Science
Kashofer, K; Gornicec, M; Caraffini, V; Lind, K; Schauer, S; Beham-Schmid, C; Wölfler, A; Hoefler, G; Sill, H; Zebisch, A
Genetic aberrations of myeloid sarcomas
memo - Magazine of European Medical Oncology
. 2017; 10(2):28-28.-Annual Meeting of the Austrian Society of Haematology and Medical Oncology
; APR 6-8, 2017; Bregenz, AUSTRIA.
[Poster]
Neumeister, P; Spindelboeck, W; Zinke-Cerwenka, W; Schulz, E; Hoegenauer, C; Sill, H; Gorkiewicz, G; Kump, P; Greinix, H
Successful treatment of steroid-refractory acute gastrointestinal graft-versus-host-disease by fecal microbiota transplantation
BONE MARROW TRANSPL. 2017; 52: S232-S232.
Web of Science
Nomdedeu, M; Tuechler, H; Kuendgen, A; Sole, F; Schanz, J; Hildebrandt, B; Grau, J; Pereira, A; Garcia-Manero, G; Sekeres, MA; Komrokji, RS; Voso, MT; List, AF; Cazzola, M; Sill, H; Stauder, R; Greenberg, P; Germing, U; Sanz, G; Haase, D
CHROMOSOMAL ABERRATIONS IN THERAPY-RELATED MYELODYSPLASTIC SYNDROMES - RELATIONS TO PRIMARY DISEASE, THERAPY AND PROGNOSTIC SIGNIFICANCE
LEUKEMIA RES. .. 2017; 55: S32-S33.-14th International Symposium on Myelodysplastic Syndromes (MDS); MAY 03-06, 2017; Valencia, SPAIN.
Doi: 10.1016/S0145-2126(17)30161-3
[Poster]
Web of Science
FullText
FullText_MUG
Rollig C, Middeke JM, Stasik S, Zebisch A, Sill H, Kramer M, Scholl S, Hochhaus A, Edgar J, Brümmendorf TH, Naumann R, Steffen B, Serve H, Altmann H, Kunzmann V, Einsele H, Parmentier SB, Schaich M, Burchert A, Neubauer A, Heits F, Berdel WE, Sockel K, Stoelzel F, Platzbecker U, Ehninger G, Bornhäuser M, Schetelig J, and Thiede C.
Real World Data on Decitabine Treatment in 296 Patients with Acute Myeloid Leukemia: Outcome and Impact of TP53 Mutations
Blood. 2017; 130, suppl. 1: -American Society of Hematology; Dec7-12, 2017; Atlanta, USA.
[Poster]
Schmidt, V; Zebisch, A; Hofer, S; Steinwender, D; Höfler, G; Beham-Schmid, C; Sill, H; Wölfler, A
Analysis of criteria for tyrosine kinase Inhibitor discontinuation in CML patients in a real-life setting
memo - Magazine of European Medical Oncology. 2017; 10(2):26-26.-Annual Meeting of the Austrian Society of Haematology and Medical Oncology
; APR 6-8, 2017; Bregenz, AUSTRIA.
[Poster]
Stauber, M; Aberer, F; Oulhaj, A; Mader, JK; Zebisch, A; Pieber, TR; Neumeister, P; Greinix, HT; Sill, H; Sourij, H; Wolfler, A
Early hyperglycaemia after initiation of glucocorticoid therapy predicts adverse outcome in patients with acute graft-versus-host disease
BONE MARROW TRANSPL. 2017; 52: S285-S285.
Web of Science
Subramanian, A; Rosenberger, A; Schwarzenberger, E; Strobl, H; Zenisch, A; Sill, H; Wölfler, A
A role of C/EBPa in early dendritic cell development.
FEBS Immunology Summer School; SEP 23-30, 2017; Hvar, CROATIA. 2017.
[Poster]
Thomas Bärnthaler, Katharina Jandl, Rudolf Schicho, Barbara Uhl, Florian Reichmann, Magdalena Grill, Gunther Marsche, Heinz Sill, Akos Heinemann, Rufina Schuligoi
Imatinib inhibits TNFα via PGE2 and the EP4 receptor
23rd Scientific Symposium of
the Austrian Pharmacological Society APHAR; Sept 28-29, 2017; Insbruck, Austria. 2017.
[Poster]
Thomas Bärnthaler, Katharina Jandl, Rudolf Schicho, Barbara Uhl, Florian Reichmann, Magdalena Grill, Gunther Marsche, Heinz Sill, Akos Heinemann,Rufina Schuligoi
Imatinib inhibits TNF-alpha expression via PGE2 and the EP4 receptor
ÖGMBT Annual Meeting 2017, Molecular and cellular mechanisms of human diseases; Sept 25-27, 2017; Innsbruck, Austria. 2017.
[Poster]
Thomas Bärnthaler, Katharina Jandl, Rudolf Schicho, Barbara Uhl, Florian Reichmann, Magdalena Grill, Gunther Marsche, Heinz Sill, Akos Heinemann,Rufina Schuligoi
Imatinib inhibits TNF-alpha expression via PGE2 and the EP4 receptor
Doctoral Day of the Medical University of Graz 2017; Dec 13, 2017; Graz, Austria. 2017.
[Poster]
Unterluggauer, J; Beham-Schmid, C; Sill, H; Tomazic, PV; Fechter, K; Schicho, R; Neumeister, P; Deutsch, A; Haybaeck, J
Expression analysis indicates implication of translation initiation factors in development of aggressive B-cell lymphomas.
OeGHO Frühjahrstagung 2017; APR 6-8, 2017; Bregenz, AUSTRIA. 2017.
[Poster]
Unterluggauer, J; Beham-Schmid, C; Sill, H; Tomazic, PV; Fechter, K; Schicho, R; Neumeister, P; Deutsch, A; Haybaeck, J
Retrospective study: Expression analysis in malignant lymphomas reveals eIF impact.
International Student Congress Graz; MAY 25-27, 2017; Graz, AUSTRIA. 2017.
[Oral Communication]
Unterluggauer, J; Beham-Schmid, C; Sill, H; Tomazic, PV; Schicho, R; Neumeister, P; Deutsch, A; Haybaeck, J
Eukaryontische Translations-Initiationsfaktoren und ihr Einfluss auf lymphatische Neoplasien.
101. Jahrestagung der Deutschen Gesellschaft für Pathologie; JUN 22-24, 2017; Erlangen, GERMANY. 2017.
[Oral Communication]
Unterluggauer, J; Beham-Schmid, C; Tomazic, PV; Fechter, K; Rinner, B; Pichler, M; Weniger, M; Kueppers, R; Sill, H; Schicho, R; Neumeister, P; Deutsch, A; Haybaeck, J;
Translation initiation factors as novel prognostic biomarkers of aggressive B-cell lymphomas.
29th European Congress of Pathology; SEP 2-6, 2017; Amsterdam, NETHERLANDS. 2017.
[Oral Communication]
Unterluggauer, J; Beham-Schmid, C; Tomazic, PV; Fechter, K; Rinner, B; Pichler, M; Weniger, M; Kuppers, R; Sill, H; Schicho, R; Neumeister, P; Deutsch, A; Haybaeck, J
Translation initiation factors as novel prognostic biomarkers of aggressive B-cell lymphomas
VIRCHOWS ARCH. 2017; 471: S43-S43.
[Poster]
Web of Science
Unterluggauer, J; Beham-Scmid, C; Tomazic, PV; Fechter, K; Rinner, B; Pichler, M; Weniger, M; Kueppers, R; Sill, H; Schicho, R; Neumeister, P; Deutsch, A; Haybaeck, J
Comprehensive expression analysis indicates translation initiation factors as novel biomarkers for aggressive B-cell lymphomas.
Herbsttagung der ÖGPath/IAP Austria; SEP 14-16, 2017; Velden, AUSTRIA. 2017.
[Poster]
Unterluggauer, J; Seeboeck, R; Tomazic, PV; Huber, HJ; Fechter, K; Steinbauer, E; Rinner, B; Pichler, M; Weniger, M; Kueppers, R; Sill, H; Schicho, R; Neumeister, P; Beham-Schmid, C; Deutsch, A; Haybaeck, J
Comprehensive expression analysis indicates translation initiation factors as novel biomarkers for aggressive B-cell lymphomas
Doctoral Day 2017 Medical University of Graz; DEZ 13, 2017; Graz, AUSTRIA. 2017.
[Poster]
Aberer, F; Kremser, S; Zebisch, A; Mader, JK; Sill, H; Greinix, H; Zinke-Cerwenka, W; Pieber, TR; Oulhaj, A; Wölfler, A; Sourij, H
Hyperglycemia during the First Month after Allogeneic Hematopoietic
Stem Cell Transplantation Is an Independent Risk Factor for
Overall Survival in Patients with Acute Myeloid Leukemia.
Diabetes. 2016; 65(S1):A410-A411.-76th Scientific Sessions of the American Diabetes Association (ADA); JUN 10-14, 2016; New Orleans, LA, USA.
[Poster]
Aberer, F; Stauber, M; Zebisch, A; Greinix, H; Sill, H; Mader, JK; Oulhaj, A; Pieber, TR; Wölfler, A; Sourij, H
In-Hospital Hyperglycemia Is Associated with Adverse Outcome in
Patients with Acute or Chronic Graft vs. Host Disease after Hematopoeietic Stem Cell Transplantation.
Diabetes. 2016; 65(S1):A390-A390.-76th Scientific Sessions of the American Diabetes Association (ADA); JUN 10-14, 2016; New Orleans, LA, USA.
[Poster]
Bainschab, A; Quehenberger, F; Greinix, HT; Krause, R; Wölfler, A; Sill, H; Zebisch, A
Antibiotic prophylaxis is associated to a decreased rate of infections in AML patients treated with low-intensity therapeutic regimens
memo - Magazine of European Medical Oncology . 2016; 9(1):20-20.-Annual Meeting of the Austrian Society of Haematology and Medical Oncology; MAR 17-19, 2016; Vienna, AUSTRIA.
[Poster]
Gaksch, L; Kashofer, K; Daga, S; Hofer, S; Höfler, G; Zebisch, A; Sill, H; Wölfler A
Mutation clearance detected by parallel
sequencing at end of treatment: impact on
relapse-free survival in intermediate-risk AML
patients
memo - Magazine of European Medical Oncology . 2016; 9(1):3-3.-Annual Meeting of the Austrian Society of Haematology and Medical Oncology; MAR 17-19, 2016; Vienna, AUSTRIA.
[Oral Communication]
Gaksch, L; Kashofer, K; Heitzer, E; Daga, S; Hofer, S; Krisper, N; Höfler, G; Zebisch, A; Sill, H; Wölfler A
Persitence of non-DNMT3A mutations predicts relapse in cytogenetically normal AML.
Oncol Res Treat 2016. 2016; 39(suppl3):140--Jahrestagung DGHO; OCT 14-18,2016; Leipzig. (ISBN: 2296-5270 )
[Oral Communication]
Web of Science
Geissler, K; Barna, A; Jäger, E; Alendar, T; Ljubuncic, E; Jilch, R; Nösslinger, T; Pfeilstöcker, M; Tüchler, H; Reisner, R; Sliwa, T; Keil, F; Burgstaller, S; Thaler, J; Machherndl-Spandl, S; Zach, O; Weltermann, A; Bettelheim, P; Stauder, R; Schwarzinger, I; Hörmann, G; Jäger, U; Sperr, WR; Knöbl, P; Schneeweiss, B; Berger, J; Kusec, R; Öhler, L; Zebisch, A; Sill, H; Germing, U; Valent, P
Clinical, Hematological, and Biologic Characteristics in Chronic Myelomonocytic Leukemia Patients with a JAK2 V617F Mutation
Blood. 2016; 128(22):-Annual Meeting of the American Society of Hematology; DEC 3-6, 2016; San Diego, USA.
[Poster]
Geissler, K; Barna, A; Jäger, E; Alendar, T; Ljubuncic, E; Jilch, R; Nösslinger, T; Pfeilstöcker, M; Tüchler, H; Reisner, R; Sliwa, T; Keil, F; Burgstaller, S; Thaler, J; Machherndl-Spandl, S; Zach, O; Weltermann, A; Bettelheim, P; Stauder, R; Schwarzinger, I; Hörmann, G; Jäger, U; Sperr, WR; Knöbl, P; Schneeweiss, B; Berger, J; Kusec, R; Öhler, L; Zebisch, A; Sill, H; Germing, U; Valent P
High Spontaneous In Vitro Myeloid Colony Formation in Chronic Myelomonocytic Leukemia is Associated with Mutations in Rasopathy Genes, Myeloproliferation and Inferior Prognosis
Blood. 2016; 128(22):-Annual Meeting of the American Society of Hematology; DEC 3-6, 2016; San Diego, USA.
[Poster]
Heidenreich, S; Ziagkos, D; van Biezen, A; Finke, J; Platzbecker, U; Niederwieser, D; Einsele, H; Bethge, WA; Schleuning, M; Beelen, DW; Tischer, J; Nagler, A; Glass, B; Maertens, J; Richard, C; Beguin, Y; Sill, H; de Witte, T; Robin, M; Kroger, N
Allogeneic Stem Cell Transplantation for MDS Patients More Than 70 Years of Age: Update of a Retrospective Study of the MDS Subcommittee of the Chronic Malignancies Working Party (CMWP) of the EBMT
BONE MARROW TRANSPL. 2016; 51: S510-S511.-42nd Annual Meeting of the European-Society-for-Blood-and-Marrow-Transplantation; APR 03-06, 2016; Valencia, SPAIN.
[Oral Communication]
Web of Science
Lal, R; Lind, K; Kashofer, K; Heitzer, E; Ulz, P; Troppmair, J; Hofer, S; Schulz, E; Mathre, K; Wölfler, A; Zebisch, A; Sill, H
TP53 mutations in acute myeloid leukemia affect pre-leukemic stem cells
memo - Magazine of European Medical Oncology . 2016; 0(1):19-20.-Annual Meeting of the Austrian Society of Haematology and Medical Oncology; MAR 17-19, 2016; Vienna, AUSTRIA.
[Poster]
Lerch K, Leng C, Pinto A, Linkesch W, Sill H, Linden O, Viardot A, Keller U, Hess G, Lastoria S, Frigeri F, Neik N, Pott C, Scholz CW and Pezzutto A
90Yttrium-Ibritumomab Tiuxetan as First Line Treatment for Follicular Non-Hodgkin Lymphoma. 5 Year Results from an International Multicenter Phase II Clinical Trial
Blood. 2016; 128(22):-Annual Meeting of the American Society of Hematology; December 2016; San Diego, FL.
[Poster]
Magina, N; Pregartner, G; Berghold, A; Sill, H
Conventional post-remission therapy in adult acute myeloid leukemia - a systematic review/meta-analysis
WIEN KLIN WOCHENSCHR. 2016; 128: S385-S385.
[Poster]
Web of Science
Olipitz, W; Lind, K; Monsberger, N; Katschnig, A; Mangerich, A; Rankl, J; Hofer, S; Mueller, M; Schulz, E; Quehenberger, F; Schlembach, D; Robier, C; Woelfler, A; Zebisch, A; Sill, H
IMPAIRED BASE EXCISION REPAIR GLYCOSYLASE/AP ENDONUCLEASE ACTIVITY CONTRIBUTES TO CYTARABINE RESISTANCE IN ACUTE MYELOID LEUKEMIA
HAEMATOLOGICA. 2016; 101: 211-212.
[Poster]
Web of Science
Schulz, E; Lind, K; Renner, W; Petersen, BS; Dill, C; Hofer, S; Lal, R; Quehenberger, F; Stolzel, F; Sill, H
THE HOMOZYGOUS TP53 P72R SNP IS ASSOCIATED WITH NON-FAVORABLE CYTOGENETIC RISK GROUPS IN ACUTE MYELOID LEUKEMIA
HAEMATOLOGICA. 2016; 101: 383-383.
[Poster]
Web of Science
Stauber, M; Aberer, F; Zebisch, A; Neumeister, P; Greinix, HT; Sill, H; Sourij, H; Wölfler, A
Steroid-induced hyperglycemia adversely impacts outcome in graft-versus-host disease
memo - Magazine of European Medical Oncology . 2016; 9(1):21-21.-Annual Meeting of the Austrian Society of Haematology and Medical Oncology; MAR 17-19, 2016; Vienna, AUSTRIA.
[Poster]
Thomas Bärnthaler, Katharina Jandl, Rudolf Schicho, Barbara Uhl, Florian Reichmann, Magdalena Grill, Gunther Marsche, Heinz Sill, Akos Heinemann,Rufina Schuligoi
Imatinib inhibits TNF-alpha expression via PGE2 and the EP4 receptor
22nd Scientific Symposium of the Austrian Pharmacological Society Joint meeting with the Hungarian Society for Experimental and Clinical Pharmacology ; Dec 8-10, 2016; Vienna, Austria. 2016.
[Poster]
Thomas Bärnthaler, Katharina Jandl, Rudolf Schicho, Barbara Uhl, Florian Reichmann, Magdalena Grill,Gunther Marsche, Heinz Sill, Akos Heinemann,Rufina Schuligoi
Imatinib inhibits TNF-alpha expression via PGE2 and the EP4 receptor
Doctoral Day of the Medical University of Graz; Dec 14, 2016; Graz Austria. 2016.
[Poster]
Unterluggauer, J; Beham-Schmid, C; Sill, H; Tomazic, PV; Schicho, R; Neumeister, P; Deutsch, A; Haybaeck, J
Eukaryotic translation Initiation Factors impact lymphatic neoplastic disorders.
Doctoral Day 2016 Medical University of Graz; DEZ 14, 2016; Graz, AUSTRIA. 2016.
[Poster]
Zebisch, A; Lal, R; Muller, M; Lind, K; Sill, H
TP53 germline mutations occur in acute myeloid leukemia and are associated with therapy-related cases following ionizing radiation
WIEN KLIN WOCHENSCHR. 2016; 128: S385-S386.
[Poster]
Web of Science
Aberer, F; Mader, JK; Kremser, S; Zinke-Cerwenka, W; Greinix, H; Pieber, TR; Zebisch, A; Sill, H; Oulhaj, A; Wölfler, A; Sourij, H
Glykämie nach allogener Stammzelltransplantation bei Patienten mit akuter myeloischer Leukämie (AML) ist ein unabhängiger Prädiktor für das Überleben.
Wiener Klinische Wochenschrift. 2015; 127(Suppl 4 ):S135-S135.-43. Jahrestagung der Österreichischen Diabetes Gesellschaft (ÖDG); NOV 19-21, 2015; Salzburg, AUSTRIA.
[Poster]
Web of Science
Bainschab, A; Quehenberger, F; Greinix, HT; Krause, R; Wolfler, A; Sill, H; Zebisch, A
Efficacy of antibiotic prophylaxis in AML patients treated with low-intensity therapeutic regimens
ONCOL RES TREAT. 2015; 38: 73-74.
[Poster]
Web of Science
Gaksch, L; Kashofer, K; Höfler, G; Tinchon, C; Krippl, P; Zebisch, A; Greinix, H; Sill, H; Wölfler, A
Feasibility of next generation sequencing for routine diagnostic genetic profiling in myeloid malignancies.
memo-magazine of european medical oncology; 2015 Proceedings of the Annual Meeting of the Austrian Society for Haematology and Medical Oncology.. 2015; 8(1):-Annual Meeting of the Austrian Society of Haematology and Medical Oncology; APR 23-25, 2015; Salzburg, AUSTRIA.
[Poster]
Hatzl, S; Geiger, O; Kuepper, MK; Seime, T; Nußbaumer, E; Wieser, R; Pichler, M; Scheideler, M; Nowek, K; Jongen-Lavrencic, M; Wölfler, A; Troppmair, J; Sill, H; Zebisch, A
Loss of the tumor- and metastasis suppressor RAF kinase inhibitor protein is caused by the overexpression of miRNA-23a
Oncology Research and Treatment. 2015; 38: -Annual Meeting of the German, Austrian and Swiss Associations of Hematology and Medical Oncology; OKT 9-13, 2015; Basel, SWITZERLAND. (ISBN: 978-3-318-02811-9 )
[Oral Communication]
Hatzl, S; Geiger, O; Kuepper, MK; Seime, T; Nussbaumer, E; Wieser, R; Pichler, M; Scheideler, M; Nowek, K; Jongen-Lavrencic, M; Wolfler, A; Troppmair, J; Sill, H; Zebisch, A
Loss of the tumor- and metastasis suppressor RAF kinase inhibitor protein is caused by the overexpression of miRNA-23a
ONCOL RES TREAT. 2015; 38: 99-99.
[Oral Communication]
Web of Science
Hatzl, S; Geiger, O; Nußbaumer, E; Rosenberger, A; Troppmair, J; Kolch, W; Blyth, K; Sill, H; Woelfler, A; Zebisch, A
RAF kinase inhibitor protein is involved in the myelomonocytic differentiation of hematopoietic progenitors.
memo-magazine of european medical oncology; 2015 Proceedings of the Annual Meeting of the Austrian Society for Haematology and Medical Oncology.. 2015; 8(S1):-Annual Meeting of the Austrian Society of Haematology and Medical Oncology; APR 23-25, 2015; Salzburg, AUSTRIA.
[Poster]
Heidenreich, S; Ziagkos, D; van Biezen, A; Finke, J; Platzbecker, U; Niederwieser, D; Einsele, H; Bethge, WA; Schleuning, M; Beelen, DW; Tischer, J; Nagler, A; Class, B; Maertens, J; Richard, C; Beguin, Y; Sill, H; de Witte, T; Robin, M; Kroeger, N
Allogeneic Stem Cell Transplantation for MDS Patients More Than 70 Years of Age: a Retrospective Study of the MDS Subcommittee of the Chronic Malignancies Working Party (CMWP) of the EBMT
BLOOD. 2015; 126(23):-55th Annual Meeting and Exposition of the American-Society-of-Hematology; DEC 07-10, 2013; New Orleans, LA.
[Oral Communication]
Web of Science
Kremser, S; Aberer, F; Zinke-Cerwenka, W; Neumeister, P; Zebisch, A; Greinix, H; Sill, H; Sourij, H; Wölfler, A
Hyperglycemia is an adverse risk factor in AML patients undergoing allogeneic hematopoietic stem cell transplantation.
memo-magazine of european medical oncology; 2014 Proceedings of the Annual Meeting of the Austrian Society for Haematology and Medical Oncology.. 2015; 8(S1):-Annual Meeting of the Austrian Society of Haematology and Medical Oncology; APR 23-25, 2015; Salzburg, AUSTRIA.
[Poster]
Nußbaumer, E; Hatzl, S; Kuepper, K; Geiger, O; Wieser, R; Pichler, M; Scheideler, M; Nowek, K; Lavrencic, M; Woelfler, A; Troppmair, J; Sill, H; Zebisch, A
Loss of RAF kinase inhibitor protein in acute myeloid leukemia is caused by the overexpression of miRNA-15a.
memo-magazine of european medical oncology; 2015 Proceedings of the Annual Meeting of the Austrian Society for Haematology and Medical Oncology.. 2015; 8(1):-Annual Meeting of the Austrian Society of Haematology and Medical Oncology; APR 23-25, 2015; Salzburg, VIENNA.
[Poster]
Pleyer, L; Burgstaller, S; Stauder, R; Girschikofsky, M; Sill, H; Schlick, K; Thaler, J; Halter, B; Machherndl-Spandl, S; Zebisch, A; Pichler, A; Pfeilstöcker, M; Autzinger, EM; Lang, A; Geissler, K; Voskova, D; Geissler, D; Sperr, WR; Hojas, S; Mandac-Rogulj, I; Andel, J; Greil, R
Is it time to redefine response or treatment failure in elderly patients with WHO-AML unfit for intensive chemotherapy?
Blood 2015. 2015; 126(23):-Annual meeting of the American Society of Hematology; DEC 5-8, 2015; Orlando, USA.
[Poster]
Web of Science
Pleyer, L; Burgstaller, S; Stauder, R; Girschikofsky, M; Sill, H; Schlick, K; Thaler, J; Halter, B; Machherndl-Spandl, S; Zebisch, A; Pichler, A; Pfeilstöcker, M; Autzinger, EM; Lang, A; Geissler, K; Voskova, D; Geissler, D; Sperr, WR; Hojas, S; Mandac-Rogulj, I; Andel, J; Greil, R
Azacitidine in acute myeloid leukemia with >30% bone marrow blasts and <15 G/L white blood cell count: Results from the Austrian Azacitidine Registry of the AGMT Study Group versus randomized controlled phase III clinical trial data.
Blood 2015. 2015; 126(23):-Annual Meeting of the American Society of Hematology; DEC 5-8, 2015; Orlando, USA.
[Poster]
Web of Science
Rosenberger, A; Geiger, O; Zebisch, A; Sill, H; Wolfler, A
C/EBP alpha-induced proinflammatory cytokines regulate early dendritic cell development
ONCOL RES TREAT. 2015; 38: 249-250.
[Poster]
Web of Science
Stauber, M; Aberer, F; Zebisch, A; Neumeister, P; Greinix, HT; Sill, H; Sourij, H; Wolfler, A
Steroid-induced hyperglycemia adversely impacts outcome in graft-versus-host disease
ONCOL RES TREAT. 2015; 38: 129-129.
[Poster]
Web of Science
Vilits, T; Huber-Krassnitzer, B; Zinke-Cerwenka, W; Neumeister, P; Quehenberger, F; Hoenigl, M; Sill, H; Woffler, A
Impact of linezolid on hematopoietic engraftment in patients after umbilical cord blood stem cell transplantation
BONE MARROW TRANSPL. 2015; 50: S192-S192.-41st Annual Meeting of the European-Society-for-Blood-and-Marrow-Transplantation; MAR 22-25, 2015; Istanbul, TURKEY.
[Poster]
Web of Science
Zebisch, A; Schulz, E; Hatzl, S; Grosso, M; Lombardo, B; Acierno, G; Sill, H; Iolascon, A
Epsilon-gamma-delta-beta° thalassemia Austrian I: identification of a novel hemoglobinopathy.
memo-magazine of european medical oncology; 2015 Proceedings of the Annual Meeting of the Austrian Society for Haematology and Medical Oncology.. 2015; 8(1):-Annual Meeting of the Austrian Society of Haematology and Medical Oncology; APR 23-25, 2015; Salzburg, AUSTRIA.
[Poster]
Kuepper, MK; Wolf, O; Huber-Krassnitzer, B; Wieser, R; Pichler, M; Scheideler, M; Woelfler, A; Sill, H; Zebisch, A
Overexpression of miR-23a, miR-24 and miR-15a in acute myeloid leukemia with loss of the RAF kinase inhibitor protein.
memo-magazine of european medical oncology 2014 Proceedings of the Annual Meeting of the Austrian Society for Haematology and Medical Oncology. 2014; 7(1):-Annual Meeting of the Austrian Society for Haematology and Medical Oncology; APR 10-12, 2014; Innsbruck, AUSTRIA.
[Oral Communication]
Leitner,E; Zarfel,G; Luxner, J; Herzog,K; Hönigl,M; Valentin,T; Prattes,J; Feierl,G; Grisold,AJ;Högenauer,C; Sill,H; Krause,R; Zollner-Schwetz, I.
Contaminated handwashing sinks: the source of an ongoing clonal outbreak with KPC-producing Klebsiella oxytoca on a hematology ward
ÖIK. 2014; -8. Österreichischer Infektionskongress; April 2-5, 2014; Saalfelden, AUSTRIA.
[Poster]
Lind, K; Olipitz, W; Monsberger, N; Katschnig, A; Hofer, S; Schulz, E; Quehenberger, F; Schlembach, D; Robier, C; Wölfler, A; Zebisch, A; Sill, H
Defizienz der Basen-Exzisions-Reparatur (BER) bei akuter myeloischer Leukämie (AML).
memo-magazine of european medical oncology
2014 Proceedings of the Annual Meeting of the Austrian Society for Haematology and Medical Oncology. 2014; 7(1):-Annual Meeting of the Austrian Society for Haematology and Medical Oncology; APR 10-12, 2014; Innsbruck, AUSTRIA.
[Poster]
Olipitz, W; Lind, K; Monsberger, N; Katschnig, A; Mangerich, A; Hofer, S; Schulz, E; Quehenberger, F; Schlembach, D; Robier, C; Woelfler, A; Zebisch, A; Sill, H
Base Excision Repair Glycosylase Activity Is Impaired in a Subgroup of Acute Myeloid Leukemia Resulting in Increased Levels of Oxidative Base Lesions
BLOOD. 2014; 124(21):-56th Annual Meeting of the American-Society-of-Hematology; DEC 06-09, 2014; San Francisco, CA.
[Poster]
Web of Science
Olipitz, W; Lind, K; Monsberger, N; Katschnig, A; Mangerich, A; Hofer, S; Schulz, E; Quehenberger, F; Schlembach, D; Robier, C; Wölfler, A; Zebisch, A; Sill, H
Base excision repair glycosylase activity is impaired in a subgroup of acute myeloid leukemia resulting in increased levels of oxidative base lesions
Oncol Res Treat. 2014; 37(S5):49-49.-Annual Meeting of the German, Austrian and Swiss Associations of Hematology and Medical Oncology; OCT 10-14; Hamburg, GERMANY. (ISBN: 978-3-318-02811-9 )
[Poster]
Web of Science
Rosenberger, A; Wolf, O; Zebisch, A; Touw, I; Sill, H; Wölfler, A
Myeloid progenitors contribute to formation of plasmacytoid dendritic cells in the thymus.
memo-magazine of european medical oncology
2014 Proceedings of the Annual Meeting of the Austrian Society for Haematology and Medical Oncology. 2014; 7(1):-Annual Meeting of the Austrian Society for Haematology and Medical Oncology; APR 10-12, 2014; Innsbruck, AUSTRIA.
[Poster]
Sadovnik, I; Herrmann, H; Stefanzl, G; Berger, D; Hoermann, G; Blatt, K; Cerny-Reiterer, S; Sperr, WR; Sill, H; Valent, P
EFFECTS OF THE PI3-KINASE/MTOR INHIBITOR BEZ235 ON ONCOGENIC SIGNALING, PROLIFERATION AND SURVIVAL OF LEUKEMIC CELLS IN CML
HAEMATOLOGICA. 2014; 99: 67-67.-19th Congress of the European-Hematology-Association; JUN 12-15, 2014; Milan, ITALY.
[Poster]
Web of Science
Sadovnik, I; Herrmann, H; Stefanzl, G; Berger, D; Hoermann, G; Blatt, K; Cerny-Reiterer, S; Sperr, WR; Sill, H; Valent, P
The PI3K/mTOR blocker BEZ235 and BCR/ABL TKIs exert synergistic growth-inhibitory effects in CML cells
ONCOL RES TREAT. 2014; 37: 56-56.
[Poster]
Web of Science
Schmidt, S; Sill, H; Greil, R; Burgstaller, S; Schlogl, E; Petzer, A
UPDATED REPORT OF THE AUSTRIAN CML REGISTRY
HAEMATOLOGICA. 2014; 99: 341-341.-19th Congress of the European-Hematology-Association; JUN 12-15, 2014; Milan, ITALY.
[Poster]
Web of Science
Schmidt, S; Sill, H; Greil, R; Burgstaller, S; Sliwa, T; Petzer, A; Lang, A; Weltermann, A; Voskova, D; Mitterer, M; Valent, P; Eberhard, N; Walder, A; Geissler, K; Andel, J; Hausler, C; Ludescher, C; Oexle, H; Korger, M; Schnallinger, M; Schreieck, S; Krippl, P; Pober, M; Woell, E; Geissler, D; Rochau, U; Siebert, U; Thaler, J; Gastl, G
Updated report of the Austrian CML registry
ONCOL RES TREAT. 2014; 37: 57-58.
[Poster]
Web of Science
Schulz, E; Kashofer, K; Mhatre, KN; Höfler, G; Sill, H
SELECTION OF A PRE-EXISTING TP53 MUTATED CLONE IN THERAPY-RELATED ACUTE MYELOID LEUKEMIA
Haematologica. 2014; 99(S1):15-15.-19th Congress of the European Hematology Association; JUNE 12-15, 2014; Milan, ITALY.
[Poster]
Web of Science
FullText
Schulz, E; Kashofer, K; Mhatre, KN; Höfler, G; Sill H
Selektion eines prä-existenten TP53 mutierten Klons durch zytotoxische Behandlung bei einem Patienten mit Therapie-assoziierter AML (t-AML)
memo-Magazine of European Medical Oncology, Proceedings of the Annual Meeting of the Austrian Society of Haematology and Medical Oncology. 2014; 7(1):-Annual Meeting of the Austrian Society for Haematology and Medical Oncology; APR 10-12, 2014; Innsbruck, AUSTRIA.
[Poster]
FullText
Schulz, E; Klampfl, P; Holzapfel, S; Janecke, AR; Ulz, P; Renner, W; Kashofer, K; Najima, S; Leitner, A; Zebisch, A; Wölfler, A; Hofer, S; Gerger, A; Lax, S; Beham-Schmid, C; Steinke, V; Geigl, JB; Höfler, G; Speicher, MR; Boland, CR; Kumanogoh, A; Sill, H
Germline variants in the semaphorin SEMA4A confer susceptibility to familial colorectal cancer type X
Oncol Res Treat. 2014; 37(S5):105-105.-Annual Meeting of the German, Austrian and Swiss Associations of Hematology and Medical Oncology; OCT 10-14, 2014; Hamburg, GERMANY. (ISBN: 978-3-318-02811-9 )
[Oral Communication]
Web of Science
Valentin T, Lutfi A, Zollner-Schwetz I, Wagner J, Hoenigl M, Sill H, Krause R
Fulminant Liver Gas Gangrene presenting as Thoracic and Abdominal Pain with Severe Haemolysis
www.oegit.eu. 2014; -8. Österreichsicher Infektionskongress; APR 2-5, 2014; Saalfelden, AUSTRIA.
[Poster]
Wolf, O; Schulz, E; Theiler, G; Troppmair, J; Kolch, W; Haller, M; Woelfler, A; Sill, H; Zebisch, A
RAF kinase inhibitor protein inhibits 1,25-dihydroxyvitamin D3 induced myelomonocytic differentiation of HL-60 acute myeloid leukemia cells.
memo-magazine of european medical oncology
2014 Proceedings of the Annual Meeting of the Austrian Society for Haematology and Medical Oncology. 2014; 7(1):-Annual Meeting of the Austrian Society for Haematology and Medical Oncology; APR 10-12, 2014; Innsbruck, AUSTRIA.
[Poster]
Wölfler, A; Rosenberger, A; Wolf, O; Zebisch, A; Touw, IP; Sill, H
A role of C/EBP-Alpha in Development of Plasmacytoid Dendritic Cells in the Thymus
Haematologica. 2014; 99(S1):174-174.-19th Congress of European Hematology Association; JUN 12-15, 2014; Milan, ITALY.
[Poster]
Web of Science
Zebisch, A; Wolf, O; Rosenberger, A; Petricevic, P; Hatzl, S; Troppmair, J; Kolch, W; Blyth, K; Haller, M; Sill, H; Woelfler, A
RAF kinase inhibitor protein is involved in the regulation of myelomonocytic differentiation.
Oncol Res Treat. 2014; 37(S5):49-49. 2014; 37(S5):24-24.-Annual Meeting of the German, Austrian and Swiss Associations of Hematology and Medical Oncology; OCT 10-14; Hamburg. (ISBN: 978-3-318-0281 )
[Oral Communication]
Web of Science
Cerny-Reiterer S, Blatt K, Herrmann, Eisenwort G, Herndlhofer S, Sill H, Rabitsch W, Mannhalter C, Hauswirth A, Sperr WR, Jaeger U and Valent P
Phenotyping Of Leukemic Stem Cells In Ph+ ALL and Ph- ALL Reveals Unique Profiles Of Markers and Targets In Distinct Disease Variants
Hematology 2013. 2013; -Annual Meeting,American Sociey of Hematology; December 2013; New Orleans.
[Poster]
Cerny-Reiterer, S; Herrmann, H; Blatt, K; Sadovnik, I; Eisenwort, G; Mitterbauer-Hohendanner, G; Mannhalter, C; Hauswirth, A; Sperr, WR; Sill, H; Jager, U; Valent, P
Phenotype and Target Expression Profiles of Leukemic Stem Cells in Ph plus and Ph- Acute Lymphoblastic Leukemia (ALL)
ONKOLOGIE. . 2013; 36: 182-183.
[Poster]
Web of Science
Duettmann, W; Koidl, C; Huber-Krassnitzer, B; Waitzl, B; Neumeister, P; Wagner, J; Seeber K; Sill H; Wölfler, A; Krause, R; Hoenigl, M
Serum and Urine Galactomannan Testing for Screening in Patients with Hematological Malignancies.
. 2013; -53 rd Interscience Conference on Antimicrobial Agents and Chemotherapy (ICAAC); SEP 10-13, 2013; Denver, USA..
[Poster]
Hoenigl, M; Koidl, C; Duettmann, W; Huber-Krassnitzer, B; Waitzl, B; Neumeister, P; Posch, V; Seeber, K; Wagner, J; Sill, H; Wolfler, A; Krause, R;
Serum and urine galactomannan testing for screening in patients with hematological malignancies.
MYCOSES. 2013; 56: 85-85.-6th Trends in Medical Mycology; OCT 11-14, 2013; Kopenhagen, DENMARK.
Web of Science
Orendi, K; Emberger, W; Hoefler, G; Speicher, M.R.; Sill, H;
Wert der molekularen Zytogenetik und multiplex RT-PCR in der Risikostratifizierung der akuten myeloischen Leukämie.
Proceedings of the Annual Meeting of the Austrian Society of Haematology and Oncology, MEMO (Magazine of European Medical Oncology), Suppl 01/13. 2013; 6(1):-Frühjahrstagung 2013 der Österreichischen Gesellschaft für Hämatologie & Onkologie; APR 18-20,2013; Linz, AUSTRIA.
[Oral Communication]
Orendi, K; Emberger, W; Hoefler, G; Speicher, MR; Sill, H;
Diagnostic value of molecular cytogenetics and multiplex RT-PCR for
risk stratification in acute myeloid leukemia.
European Journal of Human Genetics. 2013; 21, Supplement 2: 525-525.-European Human Genetics Conference 2013; JUNE 8-11, 2013; Paris, FRANCE.
Sadovnik I, Hermann H, Stefanzl G, Hörmann G, Blatt K, Cerny-Reiterer S, Sperr W, Sill H, Valent P.
Effects of the PI3-Kinase/mTOR blocker BEZ235 on oncogenic signaling and proliferation of leukemic cells in CML
MEMO 2013;11(Suppl 01/13). 2013; -Frühjahrstagung, Österr. Gesellschaft für Hämatologie & Medizinische Onkologie; April 2013; Linz.
[Poster]
Sill H
Therapy-related myeloid neoplasms - biology and treatment
Generalversammlung - Österr. Krebshilfe Tirol; 2013-03-18; Innsbruck. 2013.
[Keynote lecture]
Hoenigl, M; Salzer, HJ; Raggam, RB; Valentin, T; Valentin, A; Woelfler, A;Seeber, K; Strohmaier, A; Zollner-Schwetz, I; Sill H; Krause, R..
Impact of Testing Posaconazole Plasma Concentrations on Epidemiology of Antifungal Prophylaxis and Therapy in Patients with Hematologic Malignancies
. 2012; -5th Advances Against Aspergillosis; JAN 25-28, 2012; Istanbul, TURKEY.
[Poster]
Rankl J, Flicker K, Valentin A, Horn M, Uranüs S, Groselj-Strele A, Emberger W, Sill H
Hypersensitivty to alkylation treatment of primary fibroblasts from patients with therapy-related myeloid neoplasms
MEMO 2012, 12:9. 2012; -Annual Meeting, Austrian Society of Haematology and Oncology; April 2012; Graz.
[Poster]
Schulz, E; Valentin, A; Ulz, P; Beham-Schmid, C; Lind, K; Rupp, V; Lackner, H; Wolfler, A; Zebisch, A; Olipitz, W; Geigl, JB; Berghold, A; Speicher, MR; Sill, H
Germ-line mutations in cancer predisposing genes BRCA1, BRCA2, BARD1 and TP53 in patients with therapy-related myeloid neoplasms.
ONKOLOGIE. Onkologie. 2012; 35: 117-117.-Annual Meeting of the German, Austrian and Swiss Associations of Hematology and Medical Oncology; OCT 19-23, 2012; Stuttgart, GERMANY.
[Poster]
Web of Science
Sill H, Tinchon C, Hojas S, Horvath K, Wölfler A
AML: ein evidenzbasiertes SOP
Annual Meeting, Austrian Society of Haematology and Oncology; April 2012; Graz. 2012.
[Keynote lecture]
Unteregger, M; Valentin, A; Linkesch, W; Sill, H; Wölfler, A
Therapy-related myeloid neoplasms versus myeloid neoplasms following a primary malignancy treated with surgery alone.
Magazine of european medical oncology Suppl 01/12. 2012; 9-9.-Frühjahrstagung 2012 der Österreichischen Gesellschaft für Hämotologie & Onkologie; APR 12-14, 2007; Graz, Austria.
[Poster]
Hoenigl, M; Salzer, HJ; Valentin, T; Zollner-Schwetz, I; Rohn, A; Woelfler, A; Strohmaier, A; Seeber, K; Sill H; Linkesch, W; Grisold, AJ; Krause, R
Impact of galactomannan testing on epidemiology of invasive fungal infection among patients with hematologic
malignancies
. 2011; -5. Österreichischer Infektionskongress; Apr 6-9, 2011; Saalfelden, Austria.
[Poster]
Kqiku, X; Kovacs, G; Reitter, S; Sill, H; Olschewski, H
Screening for pulmonary hypertension in patients with myelodysplastic syndromes
WIEN KLIN WOCHENSCHR. . 2011; 123(17-18):A22-A23.-Jahrestagung 2011 der Österreichischen Gesellschaft für Pneumologie;
[Poster]
Web of Science
Kqiku, X; Kovacs, G; Reitter, S; Sill, H; Olschewski, H;
Exercise-induced changes of pulmonary arterial pressure in patients with myelodysplastic syndromes"
The 11th International Symposium on Myelodysplastic Syndromes2011; -The 11th International Symposium on Myelodysplastic Syndromes; May 18-21, 2011; Edinburgh,UK.
[Poster]
Kqiku X, Kovacs G, Reitter S, Sill H, Olschewski H
Exercise-induced changes of pulmonary arterial pressure in patients with myelodysplastic syndromes
Leukemia Research. 2011; 35; May 2011: -The 11th International Symposium on Myelodysplastic Syndromes 2011; May 18-21; Edinburgh, UK.
[Poster]
Kqiku X, Kovacs G, Reitter S; Sill H, Olschewski H
Pulmonary arterial pressure at rest and exercise in patients with myelodysplastic syndromes
Doctoral Day 2011; 04 November 2011; Graz; Austria. 2011.
[Oral Communication]
Linkesch, W; Neumeister, P; Zinke-Cerwenka, W; Strunk, D; Sill, H
UCBT with low-dose ATG in adults
BONE MARROW TRANSPLANT. 2011; 46: S128-S129.
[Poster]
Web of Science
Orendi, K; Sill, H; Mulabecirovic, A; Speicher, M; Emberger, W;
AML/ALL: Korrelation von klinischem Verlauf, Interphase-FISH und klassischer Zytogenetik
24.Tumorzytogenetische Arbeitstagung; MAI 16-18, 2011; Bad Ischl, AUSTRIA. 2011.
[Oral Communication]
Schulz E, Rohn A, Hiden K, Wölfler A, Beham-Schmid C, Guelly C, Lackner H, Geigl J, Speicher M, Sill H
Germ-line mutations in the DNA damage response and repair genes BRCA1, BARD1 and TP53 in patients with therapy-related myeloid neoplasms.
Haematologica 2011. 2011; 96(S2):25--Annual Meeting of the European Hematology Association; JUNE 2011; London, UK.
[Poster]
Schulz, E; Rohn, A; Lind, K; Woelfler, A; Beham-Schmid, C; Guelly, C; Lackner, H; Geigl, J; Speicher, M; Sill, H
Keimbahnmutationen in den DNA-Reparatur und Apoptose-induzierenden Genen BRCA1, BARD1 und TP53 bei Patienten mit Therapie-assoziierten myeloischen Neoplasien.
OeGHO Frühjahrstagung (Young Investigator Meeting); MAY, 5-7, 2011; Pörtschach, AUSTRIA. 2011.
[Oral Communication]
Zebisch, A; Wölfler, A; Hiden, K; Bodner, C; Fried, I; Quehenberger, F; Drasche, A; Pirkebner, D; Rath, O; Blyth, K; Matallanas, D; Taskesen, E; Kolch, W; Troppmair, J; Sill, H
RAF and RKIP in Acute Myeloid Leukemia
Fruehjahrstagung 2011 der Oesterreichischen Gesellschaft fuer Haematologie & Onkologie; Mai 5-7, 2011; Poertschach, AUSTRIA. 2011.
[Oral Communication]
Zebisch, A; Wölfler, A; Hiden K; Bodner, C; Quehenberger, F; Drasche, A; Pirkebner, D; Haller, M; Matallanas, D; Fried, I; Rath, O; Blyth, K; Taskesen, E; Kolch, W; Troppmair, J; Sill, H
RAF kinase inhibitor protein ist ein neuer Tumor-Suppressor bei der akuten myeloischen Leukämie
Onkologie. 2011; 34(S6):209-209.-Jahrestagung der Deutschen, Österreichischen und Schweizerischen Gesellschaften für Hämatologie und Onkologie; SEP 30-OCT 4, 2011; Basel, Switzerland. (ISBN: 978-3-8055-9922-1 )
[Oral Communication]
Web of Science
FullText
Zinke-Cerwenka, W; Rohn, A; Posch, U; Beham-Schmid, C; Linkesch, W; Wölfler, A; Sill, H
Graft-versus-primary malignancy in patients with therapy-related myeloid neoplasms (t-MNs) undergoing reduced-intensity allogeneic hematopoietic stem cell transplantation (HSCT).
Onkologie. 2011; 34(6):274-274.-Jahrestagung der DÖuSGHO; SEP 30-OCT 04, 2011; Basel.
[Poster]
Web of Science
Zinke-Cerwenka W, Rohn A, Posch U, Beham-Schmid C, Linkesch W, Wölfler A, Sill H.
Allogeneic stem cell transplantation with reduced intensity conditioning in patients with therapy-related myeloid neoplasms
European Surgery. 2011; 43, Suppl. 242: 22--Annual Meeting of the Austrian Society of Transplantation, Transfusion and Genetics; Oktober 2011; Graz.
[Oral Communication]
Bodner, C; Pichler, MM; Deutsch, AJ; Beham-Schmid, C; Linkesch, W; Sill, H; Wolfler, A
IDH mutations in therapy-related and secondary AML evolving from myelodysplastic syndromes.
ONKOLOGIE. 2010; 33: 232-233.-Jahrestagung der Deutschen, Österreichischen und Schweizerischen Gesellschaften für Hämatologie und Onkologie; OCT 1-5, 2010; Berlin, GERMANY.
[Poster]
Web of Science
Haller, M; Zebisch, A; Hiden, K; Hoefler, G; Sill, H; Troppmair, J
Loss of RAF kinase inhibitor protein is a somatic event in the pathogenesis of therapy-related acute myeloid leukemias with C-RAF germline mutations
FEBS J. 2010; 277: 127-127.
[Poster]
Web of Science
Kqiku X; Kovacs G; Reitter S; Sill H; Olschewski H
Prevalence of pulmonary hypertension in myelodysplastic syndrome.
Wien Klin Wochenschr (2010) 122/21-22:A47-A642010; 122: A50-A51.-Jahrestagung 2010 der österreichischen Gesellschaft für Pneumonologie; OCT 7-9, 2010; Graz.
[Poster]
Web of Science
Krieger, O; Machhemdl-Spandl, S; Hauser, H; Binder, M; Greinix, H; Eder, S; Kahls, P; Rabitsch, W; Nachbaur, D; Ludwig, H; Linkesch, W; Jaeger, G; Sill, H; Lindner, B
Stem cell transplantation for MDS patients 1987-2008: data from the Austrian transplant registry (ASCTR)
BONE MARROW TRANSPLANT. 2010; 45: S180-S181. -36th Annual Meeting of the European Group for Blood and Marrow Transplantation; MAR 21-24, 2010; Vienna, AUSTRIA.
[Poster]
Web of Science
Pichler, M; Bodner, C; Hiden, K; Linkesch, W; Sill, H; Wölfler, A
IDH1 and IDH2 mutations in patients with therapy-related and secondary AML evolving from myelodysplasia.
Memo2010; 3 Suppl. 01/10: 13--Jahrestagung der Österr. Gesellschaft für Hämatologie und Onkologie; Apri 2010; Bregenz.
[Poster]
Sill, H
Predisposition to therapy-related myeloid neoplasms
Annual Meeting of the European Group for Blood and Marrow Transplantation; 22 March 2010; Vienna. 2010.
[Oral Communication]
Zebisch, A; Woelfler, A; Hiden, K; Bodner, C; Quehenberger, F; Drasche, A; Pirkebner, D; Haller, M; Rath, O; Blyth, K; Taskesen, E; Kolch, W; Troppmair, J; Sill, H
Loss of RAF Kinase Inhibitor Protein Is a Frequent Event In Acute Myeloid Leukemia with a Monocytic Phenotype and Cooperates with Mutant RAS In Malignant Transformation
BLOOD. 2010; 116(21): 1702-1702.
[Poster]
Web of Science
Zebisch, A; Woelfler, A; Hiden, K; Bodner, C; Quehenberger, F; Drasche, A; Pirkebner, D; Rath, O; Blyth, K; Delwel, R; Taskesen, E; Kolch, W; Troppmair, J; Sill, H
LOSS OF RKIP IN ACUTE MYELOID LEUKEMIA WITH A MONOCYTIC PHENOTYPE
HAEMATOL-HEMATOL J. 2010; 95: 0026 -Annual Meting of the European Haematology Association; June 2010; Barcelona.
[Poster]
Web of Science
Hoenigl, M; Zollner-Schwetz, I; Sill, H; Linkesch, W; Lass-Flörl, C; Krause, R;
Outcome of invasive fungal infections in patients with hematologic malignancies.
Abstract Nr. 11; 3.Österreichischer Infektionskongress2009; -3.Österreichischer Infektiologiekongress der Österreichischen Gesellschaft für Infektionskrankheiten (OeGI); APR 22-25, 2009; Saalfelden, AUSTRIA.
[Poster]
Kapitan, M; Sill, H; Stadlober, E; Berghold, A
Meta-Analysis of Controlled and Uncontrolled Studies with Binary Data
ROeS Seminar 2009; SEP 13-17, 2009; Linz, AUSTRIA. 2009.
[Poster]
Olipitz, W; Scheer, N; Quehenberger, F; Hiden, K; Rankl, J; Schlembach, D; Sill, H
Base Excision Repair Deficiency in Acute Myeloid Leukemia.
BLOOD. 2009; 114(22): 454-454.
[Poster]
Web of Science
FullText
Scheer, N; Olipitz, W; Quehenberger, F; Hiden, K; Rankl, J; Schlembach, D; Sill, H
Impaired base excision repair in acute myeloid leukemia.
Memo2009; 2 (Suppl. 2): -Frühjahrstagung der Österr. Gesellschaft für Hämatologie und Onkologie; April 2009; Salzburg.
[Poster]
Sill, H
Therapy-related myeloid neoplasms - a model disease
Frühjahrstagung der Österr. Gesellschaft für Hämatologie und Onkologie; April 2009; Salzburg. 2009.
[Oral Communication]
Zebisch, A; Haller, M; Hiden, K; Rath, O; Doyle, B; Wölfler, A; Delwel, R; Kolch, W; Troppmair, J; Sill, H
Loss of the tumor suppressor RKIP in acute myeloid leukemia
Memo2009; 2 (Suppl.2): -Frühjahrstagung der Österr. Gesellschaft für Hämnatologie und Onkologie; April 2009; Salzburg.
[Oral Communication]
Kapitan, M; Sill, H; Stadlober, E; Berghold, A
Meta-analysis of controlled and uncontrolled studies: a case study and simulation results.
Proceedings of the XXIVth International Biometric Conference 20082008; -XXIVth International Biometric Conference 2008; JUL 13-18, 2008; Dublin, IRELAND.
[Poster]
Novak, M; Rosenkranz, A; Muntean, W; Zebisch, A; Sill, H; Hiden, M
Recombinant factor VIIa enhances thrombin generation in plasma of severe thrombocytopenic patients.
HAEMOPHILIA. HAEMOPHILIA2008; 14: 9-9.-World Hemophilia Congress ; JUN 2-5, 2008; Istanbul, TÜRKEI.
[Oral Communication]
Web of Science
Reitter, S; Posch, U; Eibl, M; Sill, H; Linkesch, W; Zinke-Cerwenka, W
NONMYELOABLATIVE ALLOGENEIC STEM CELL TRANSPLANTATION IN PATIENTS WITH RICHTER SYNDROME: A REPORT OF TWO CASES
HAEMATOL-HEMATOL J. 2008; 93: 1410--13th Congress of the European-Hematology-Association; JUN 12-15, 2008; Copenhagen, DENMARK.
[Poster]
Web of Science
Reitter, S; Zinke-Cerwenka, W; Zebisch, A; Sormann, S; Sill, H; Linkesch, W
Haematopoetic stem cell transplantation in CLL: promising results using allogeneic reduced intensity conditioning compared with an autologous setting
BONE MARROW TRANSPLANT. 2008; 41: S309-S310.-34th Meeting oif the EBMT; MARCH 30- APR 2, 2008; Florence, ITALY.
[Poster]
Web of Science
Zinke-Cerwenka, W; Posch, U; Sill, H; Eibl, E; Linkesch, W
FOLLOW-UP OF PATIENTS WITH MULTIPLE MYELOMA UNDERGOING AUTOLOGOUS PERIPHERAL BLOOD STEM CELL TRANSPLANTATION (PBSCT) FOLLOWED BY REDUCED-INTENSITY ALLOGENEIC PBSCT
HAEMATOL-HEMATOL J. 2008; 93: 1435
[Poster]
Web of Science
Zinke-Cerwenka, W; Posch, U; Zebisch, A; Linkesch, W; Sill, H
Results of umbilical cord blood transplantations in adults with high-risk haematologic malignancies
BONE MARROW TRANSPLANT. BONE MARROW TRANSPLANTATION.2008; 41: S158-S158.-34th Annual Meeting of the European-Group-for-Blood-and-Marrow-Transplantation/24nd Meeting of the EBMT-Nurses-Group/7th Meeting of the EBMT-Data-Management-Group; MAR 30-APR 02, 2008; Florence, ITALY.
[Poster]
Web of Science
Zinke-Cerwenka, W; Stojakovic, T; Sill, H; Eibl, E; Linkesch, W
PROMISING THERAPY RESPONSE IN MULTIPLE MYELOMA PATIENTS TREATED WITH INDUCTION CHEMOTHERAPY CONSISTING OF BORTEZOMIB, DOXORUBICIN AND DEXAMETHASONE FOLLOWED BY AUTOLOGOUS STEM CELL TRANSPLANTATION
HAEMATOL-HEMATOL J. 2008; 93: 0222--13th Congress of the European-Hematology-Association; JUN 12-15, 2008; Copenhagen, DENMARK.
[Poster]
Web of Science
Zinke-Cerwenka, W; Stojakovic, T; Zebisch, A; Sill, H; Linkesch, W
Promising results in multiple myeloma patients treated with induction chemotherapy consisting of bortezomib, doxorubicin and dexamethasone followed by autologous stem cell transplantation
BONE MARROW TRANSPLANT. 2008; 41: S185-S185.-34th Meeting of the EBMT; March 30- APR 2, 2008;
[Poster]
Web of Science
Langner, S; Staber, P; Radspieler, G; Triebl-Roth, K; Urban, C; Zinke-Cerwenka, W; Sill, H; Linkesch, W; Neumeister, P
Palifermin reduces oral mucositis and enhances the recovery of intestinal mucosa measured by citrulline serum levels in allogeneic and autologous stem cell transplant recipients
BONE MARROW TRANSPLANT. 37: S73-S74.-32nd Annual Meeting of the European-Group-for-Blood-and-Morrow-Transplantation/22nd Meeting of the EBMT-Nures-Group/5th Meeting of the EMBT-Data-Management-Group; MAR 19-22, 2006; Hamburg, GERMANY.
[Poster]
Web of Science
Langner, S; Staber, PB; Zebisch, A; Triebl-Roth, K; Urban, C; Zinke-Cerwenka, W; Sill, H; Linkesch, W; Neumeister, P
Reduced oral mucositis and enhanced intestinal mucosal recovery measured by citrulline serum levels in allogeneic and autologous stem cell transplant recipients treated with palifermin
Onkologie. 29(S3):125-126.-German, Austrian and Swiss Societies of Hematology and Oncology; NOV 4-8, 2006; Leipzig, GERMANY.
[Poster]
Zinke-Cerwenka, W; Eibl, M; Neumeister, P; Sill, H; Linkesch, W
Late effects after autologous peripheral blood stem cell transplantation followed by reduced-intensity allogeneic peripheral blood stem cell transplantation in patients with multiple myeloma
BONE MARROW TRANSPLANT. ; 37: S113-S113.-32nd Annual Meeting of the European-Group-for-Blood-and-Morrow-Transplantation/22nd Meeting of the EBMT-Nures-Group/5th Meeting of the EMBT-Data-Management-Group; MAR 19-22, 2006; Hamburg, GERMANY.
[Poster]
Web of Science
Zinke-Cerwenka, W; Neumeister, P; Eibl, M; Sill, H; Emberger, W; Wagner, T; Wolfler, A; Linkesch, W
Planned sequential autologous/non-myeloablative allogeneic peripheral stem cell transplantation in patients with newly diagnosed high-risk multiple myeloma
BONE MARROW TRANSPLANT 2005 35: S387-S388.
Web of Science
Eibl, M; Auner, H; Zinke-Cerwenka, W; Sill, H; Linkesch, W
Autologous stem cell transplantation with alemtuzumab as part of the conditioning for B-cell prolymphocytic leukaemia
BONE MARROW TRANSPLANT 2004 33: S290-S290.
Web of Science
Eibl, M; Zinke-Cerwenka, W; Neumeister, P; Wolfler, A; Sill, H; Linkesch, W
Autologous stem cell transplantation for multiple myeloma in elderly patients
BONE MARROW TRANSPLANT 2004 33: S357-S357.
Web of Science
Zebisch, A; Staber, PB; Fischereder, K; Bodner, C; Hiden, K; Linkesch, W; Auner, HW; Emberger, W; Windpassinger, C; Schimek, MG; Hoefler, G; Troppmair, J; Sill, H
Two novel activating germline mutations of the C-RAF proto-oncogene predisposing to solid tbmors and therapy-related acute myeloid leukemia.
BLOOD 2004 104: 920A-920A.
Doi: 10.1182/blood.V104.11.3370.3370
Web of Science
FullText
FullText_MUG
Zinke-Cerwenka, W; Eibl, M; Sill, H; Hofler, G; Staber, P; Linkesch, W
Continuous molecular response after discontinuation of imatinib mesylate following relapse after non-myeloablative allogeneic stem cell transplantation for CML
BONE MARROW TRANSPLANT 2004 33: S348-S348.
Web of Science
Wölfler, A; Erkeland, S; Leitner, C; Olipitz, W; Bodner, C; Wagner, T; Linkesch, W; Touw, IP; Sill, H
A functional polymorphism of the granulocyte colony-stimulating factor receptor is associated with increased risk of myelodysplastic syndrome.
BLOOD 2003 102: 915A-916A.
Web of Science
Auner, HW; Tinchon, C; Brezinschek, RI; Eibl, M; Sormann, S; Maizen, C; Linkesch, W; Schmon-Kampel, R; Sill, H
Serum cardiac troponin T (cTnT) levels, ventricular repolarization indices and echocardiographic parameters after fractionated total body irradiation and high-dose cyclophosphamide (fTBI/Cy).
BLOOD 2001 98: 5138-5138.
Web of Science
Olipitz, W; Hopfinger, G; Hoefler, G; Girschikofsky, M; Bodner, C; Hiden, K; Aguiar, R; Linkesch, W; Sill, H
Microsatellite instability but lack of alternations of genes targeted by defective DNA-mismatch repair in therapy-related MDS and leukemia.
BLOOD 2000 96: 104A-104A.
Web of Science
Schmidt, HH; Sill, H; Jager, G; Neumeister, P; Strunk, D; Linkesch, W
Capillary leak syndrome with late onset after autografting for multiple myeloma.
BONE MARROW TRANSPLANT 1998 21: S91-S91.
Web of Science
Aguiar, RCT; Sill, H; Goldman, JM; Cross, NCP
Detailed deletion map of chromosome band 9p21-22 in primary and secondary acute lymphoblastic leukaemias
BRIT J HAEMATOL. 1996; 93: 136-136.
Web of Science
Hochhaus, A; Lin, F; Reiter, A; Skladny, H; Shepherd, PCA; Sill, H; Allan, NC; Hehlmann, R; Goldman, JM; Cross, NCP
Levels of minimal residual disease in chronic myelogenous leukemia (CML) patients in complete cytogenetic remission after interferon-alpha-therapy correlate with risk of relapse.
EXP HEMATOL 1996 24: 579-579.
Web of Science
Neumeister, P; Hofler, G; BehamSchmid, C; Schmidt, H; Apfelbeck, U; Linkesch, W; Sill, H
Homozygous deletions of the p16 gene in high-grade gastric malt lymphomas.
BLOOD 1996 88: 3311-3311.
Web of Science